ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Acorda Therapeutics, Inc." (ACOR) Report Updated: Jul 28, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"Acorda Therapeutics, Inc." (ACOR)

Rating: Strong Sell Volatility: Moderate
Total Grade: F Industry: Biotechnology
Competitors: GALT, CBMG, RGEN, ANAC

Stock Analysis

Rating: Monthly View

A
B
C
D
F
July August September October November December January February March April May June

Rating: Weekly View

This Week: F down no change
Last Week: F same no change
Two Weeks Ago: F up downgrade
service keys

"Acorda Therapeutics, Inc."© quotemedia

Company Profile

Acorda Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of novel therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other central nervous system disorders primarily in the United States. Its marketed products include Ampyra (dalfampridine), a potassium channel blocker for improving walking in patients with MS; and Zanaflex Capsules and Zanaflex tablets (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The company also markets products for the improvement of walking in adult patients with MS with walking disability under the Fampyra name internationally. Its lead research and development programs include three biologic therapeutic approaches for restoring neurologic and cardiac function, which comprise Neuregulin Program for developing Glial Growth Factor 2, a molecule in the Phase I clinical trial for the treatment of heart failure; Remyelinating Antibodies Program for developing rHIgM22, an antibody in the preclinical stage for treating MS; and Chondroitinase Program, a research stage program focused on developing chontroitinase as a therapeutic to break down inhibitory factors in the scar tissue that develops as a result of an injury to the CNS. In addition, the company has in-licensed a clinical-stage program, AC105, to develop an acute treatment for neurological trauma. It has collaboration agreement with Biogen Idec International GmbH to develop and commercialize products containing aminopyridines to the treatment of MS. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.

Recent News: "Acorda Therapeutics, Inc."